Medicinal Products

ASPROFLASH 500 mg

Generic Drug Therapeutic Class: Diagnostic Products or Other Therapeutic Products
active ingredients: Acetylsalicylic acid
laboratory: Bayer Healthcare

Coated tablet
box of 20
All forms

Indication

Symptomatic treatment of febrile states and / or mild to moderate pain.

Posology ASPROFLASH 500 mg coated tablet box of 20

Symptomatic treatment of febrile states and / or mild to moderate pain.

Against indications

· Hypersensitivity to acetylsalicylic acid or other salicylates or to any of the excipients listed under Composition

· History of asthma or hypersensitivity reactions (such as urticaria, angioedema, severe rhinitis or anaphylactic shock) caused by the administration of salicylates or substances of similar activity, including nonsteroidal anti-inflammatory drugs (NSAIDs)

· Evolving gastroduodenal ulcer

· Hemorrhagic risk

· Severe renal insufficiency

· Severe hepatic insufficiency

· Severe, uncontrolled heart failure

· When methotrexate is co-administered with doses of more than 20 mg / week with acetylsalicylic acid at anti-inflammatory, analgesic or antipyretic doses (see section 4.5). Interactions with other medicinal products and other forms of interaction ).

· When co-administering oral anticoagulants with acetylsalicylic acid at anti-inflammatory, analgesic or antipyretic doses and in a patient with a history of peptic ulcer (see section 4.5). interactions ).

· From the beginning of the 6 th month of pregnancy (from the 24th week of amenorrhea) (see section on Pregnancy and lactation )

Asproflash side effects

The frequency of adverse events could not be estimated based on the available data.

Blood and lymphatic system

Tendency for bleeding and haemorrhage (epistaxis, bleeding gums, purpura, etc ...) with increased bleeding time. This risk may persist for 4 to 8 days after stopping acetylsalicylic acid. This can cause increased bleeding risk in case of surgery. Intracranial and gastrointestinal bleeding may occur.

Immune system

Hypersensitivity reactions, anaphylactic reactions, asthma, angioedema.

The nervous system

Headache, dizziness, feeling of hearing loss, tinnitus that is usually a sign of overdose.

Intracranial hemorrhage.

Gastrointestinal effects

Abdominal pain.

Digestive (hematemesis, melena, ect.) Or occult digestive hemorrhages, responsible for iron deficiency anemia. The risk of bleeding is dose-dependent.

Gastric ulcers and perforations.

Hepatobiliary disorders

Increased liver enzymes usually reversible upon discontinuation of treatment, usually hepatocellular liver lesions.

Skin and subcutaneous effects

Urticaria, cutaneous reactions.

General disorders

Reye's syndrome (see Warnings and Precautions section ).

Reporting of suspected adverse reactions

The reporting of suspected adverse reactions after authorization of the drug is important. It allows continuous monitoring of the benefit / risk ratio of the drug. Health professionals declare any suspected adverse reaction via the national reporting system: National Agency for the Safety of Medicines and Health Products (ANSM) and the network of Regional Pharmacovigilance Centers - Website: www.ansm.sante.fr

Popular Posts

Category Medicinal Products, Next Article